Gary H. Lyman, MD, MPH, FASCO, FRCP (Edin)
Co-Director, Hutchinson Institute for Cancer Outcomes Research (HICOR)
Public Health Sciences and Clinical Research Divisions
Fred Hutchinson Cancer Research Center
Professor of Medicine/Medical Oncology, University of Washington School of Medicine
Seattle Cancer Care Alliance
825 Eastlake Ave East
Seattle, WA 98109-1023
Specialty / Expertise
- Practicing medical oncologist
- Member, Public Health Sciences Division, Fred Hutchinson Cancer Research Center
- Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Comparative Effectiveness Research of Novel Diagnostic and Therapeutic Strategies
- Clinical Decision Making, Risk Modeling, and Precision Medicine
- Health Technology Assessment and Research Synthesis
- Health Disparities and Quality of Cancer Care Delivery
- Health Economics, Pharmacoeconomics and Healthcare Policy
- Cancer Treatment and Supportive Care in the Elderly
Current Research Projects
- Personalized cancer supportive care through risk stratification and targeted intervention; Systematic evidence summaries of several clinical practice topics in support of ASCO clinical practice guidelines;
- Defining and measuring the value of cancer care using multi-stakeholder engagement (HICOR)
Dr Lyman received his BA and MD through the State University of New York at Buffalo and an MPH in Biostatistics at the Harvard School of Public Health. He completed his Internal Medicine Residency at the University of North Carolina in Chapel Hill and his Fellowships in Hematology and Medical Oncology at the Roswell Park Memorial Institute as well as a postdoctoral fellowship at the Dana Farber Cancer Center in Boston.
Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2015 Dec 7. [Epub ahead of print].
Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2015 Dec 7. [Epub ahead of print] Review.
Deverka P, Messner DA, McCormack R, Lyman GH, Piper M, Bradley L, Parkinson D, Nelson D, Smith ML, Jacques L, Dutta T, Tunis SR. Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology. Genet Med. 2015 Dec 3. [Epub ahead of print].
Ma XM, Chen XH, Wang JS, Lyman GH, Qu Z, Ma W, Song JC, Zhou CK, Zhao LP. Evolving Healthcare Quality in Top Tertiary General Hospitals in China during the China Healthcare Reform (2010-2012) from the Perspective of Inpatient Mortality. PLoS One. 2015 Dec 1;10(12):e0140568.
Weycker D, Chandler D, Barron R, Xu H, Wu H, Edelsberg J, Lyman GH. Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice. J Oncol Pharm Pract. 2015 Nov 14. [Epub ahead of print].
Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Faver AM, Morrow PK, Barron RL, Asmar L, Saravanan S, Li Y, Garcia J, Lyman GH: Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients with Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices. J Natl Compr Canc Netw 2015;13 (11):1383-93.
Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG.Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2015 Nov 2.
Lyman GH, Lal L, Radtchenko J, Harrow B, Schwartzberg L. Evaluation Of Resource Utilizaton For Chemotherapy Induced Nausea And Vomiting (Cinv) In Patients Treated With Anthracycline+Cyclophosphamide (Ac) For Solid Cancers With And Without Nk-1 Based Regimens. Value Health. 2015 Nov;18(7):A465.
Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB. Evidence-based focused review of primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood. 2015 Oct 26.
Last updated: February 2016